GSK (LON:GSK) Posts Earnings Results

GSK (LON:GSK – Get Free Report) posted its quarterly earnings results on Wednesday. The company reported GBX 54.60 EPS for the quarter, Digital Look Earnings reports. GSK had a return on equity of 28.35% and a net margin of 14.52%. The firm had revenue of GBX 888.70 billion during the quarter.

GSK Stock Down 3.8%

Shares of GSK stock traded down GBX 72.50 during trading on Wednesday, reaching GBX 1,851. The company’s stock had a trading volume of 52,013,336 shares, compared to its average volume of 12,515,744. GSK has a 1-year low of GBX 1,664 and a 1-year high of GBX 2,282. The stock’s 50-day moving average price is GBX 1,850.33 and its 200 day moving average price is GBX 1,949.81. The company has a market capitalization of £74.17 billion, a price-to-earnings ratio of 15.71, a P/E/G ratio of 1.24 and a beta of 0.29. The company has a debt-to-equity ratio of 103.36, a current ratio of 0.82 and a quick ratio of 0.73.

Insider Activity

In other news, insider Jonathan Symonds acquired 1,500 shares of the stock in a transaction that occurred on Friday, September 18th. The shares were purchased at an average cost of GBX 1,881 per share, for a total transaction of £28,215. Also, insider Anne Beal acquired 637 shares of the firm’s stock in a transaction that occurred on Friday, September 18th. The shares were bought at an average cost of GBX 4,985 per share, for a total transaction of £31,754.45. Insiders bought a total of 2,151 shares of company stock valued at $6,021,921 in the last quarter. Company insiders own 0.20% of the company’s stock.

Wall Street Analysts Forecast Growth

GSK has been the subject of several analyst reports. Berenberg Bank upped their target price on GSK from GBX 2,000 to GBX 2,200 and gave the company a “hold” rating in a report on Tuesday, September 15th. Royal Bank Of Canada reiterated a “sector perform” rating and set a GBX 1,975 price target on shares of GSK in a report on Tuesday, September 8th. Jefferies Financial Group reissued a “buy” rating and set a GBX 2,500 price target on shares of GSK in a research report on Tuesday, October 20th. Finally, Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a GBX 2,000 price objective on shares of GSK in a report on Tuesday, September 29th. Two investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of GBX 2,064.38.

Get Our Latest Research Report on GSK

Key GSK News

Here are the key news stories impacting GSK this week:

GSK Company Profile

(Get Free Report)

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.

Featured Stories

Earnings History for GSK (LON:GSK)

Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.